Clinical trials: in Iran
Hemophilia A, Hemophilia
Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).
- Trial name
- NCT07791836
- Testing
- efmoroctocog alfa
- Where
- 6 sites in Iran
- Volunteers
- 262 people
- Sponsor
- AryoGen Pharmed Co.
Obesity & Overweight
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1.
- Trial name
- NCT07262762
- Where
- 14 sites in Iran
- Volunteers
- 175 people
- Sponsor
- Cinnagen
Brain Tumor, Grade III Glioma
Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
This is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Amitzo® in Iranian patients with grade III and IV glioma tumors. No control group is considered in the study design.
- Conditions
- Brain Tumor, Grade III Glioma, Grade IV Glioma
- Trial name
- NCT07675070
- Testing
- temozolomide
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- NanoAlvand
Ischemic Stroke, Stroke
Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial
The study aims to evaluate the safety and efficacy of the Supernova stent retriever device, developed by Gravity Medical Technology, for treating acute ischemic stroke.
- Conditions
- Ischemic Stroke, Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT (NCT06249776)
- Testing
- Supernova revascularization device
- Where
- 11 sites in India, Iran and 1 more
- Volunteers
- 55 people
- Sponsor
- Gravity Medical Technology, INC
Amblyopia
Evaluation of AmblyoFix for the Treatment of Unilateral Amblyopia
This is a prospective, randomized, parallel-group, assessor-masked, non-inferiority clinical trial designed to compare the efficacy, safety, and adherence of AmblyoFix binocular digital therapy with standard occlusion (patching)…
- Trial name
- NCT07240311
- Testing
- AmblyoFix binocular digital therapy, Occlusion therapy (Patching)
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Eyesight Electronics
Moderate or Severe Nasolabial Folds
Effectiveness and Safety Comparison of Lunaphil Ultra (Hyaluronic Acid, by Espad Pharmed Co.) Versus Juvederm Ultra 4® (Hyaluronic Acid, by Allergan Co.) in Nasolabial Folds (NLFs) Management
Rationale and background: Skin aging is a complex process that results in various changes in the skin, including wrinkles, sun spots, and sagging skin.
- Trial name
- NCT06509477
- Testing
- Hyaluronic acid Lunaphil Ultra (by Espad Pharmed Co.), Hyaluronic acid Juvederm Ultra 4® (by Allergan Co.)
- Where
- Iran
- Volunteers
- 104 people
- Sponsor
- Espad Pharmed
Flank Fat
Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat
Flank region fat is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid was approved by the American FDA for treatment of flank fat.
- Trial name
- NCT07004010
- Testing
- Deoxycholic Acid Injection
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Ulcerative Colitis (UC), Crohn Disease (CD)
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
The aim of this observational study is to evaluate Effectiveness and safety of VedAryo® (Vedolizumab) in male or female participants with clinical diagnosis of Inflammatory Bowel Disease. The main questions are aim to answer: 1.
- Conditions
- Ulcerative Colitis (UC), Crohn Disease (CD), Inflammatory Bowel Disease (IBD)
- Trial name
- NCT07273760
- Testing
- Vedolizumab
- Where
- 12 sites in Iran
- Volunteers
- 150 people
- Sponsor
- AryoGen Pharmed Co.
Polycythemia Vera
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera.
- Trial name
- NCT05269771
- Testing
- Ruxolitinib
- Where
- 25 sites in Australia, Belgium and 6 more
- Sponsor
- Novartis Pharmaceuticals
Submental Fullness
Effectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fat
Submental fat (SMF) is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid with the brand name KYBELLA® was approved by the American FDA for treatment of submental fat.
- Trial name
- NCT06509438
- Testing
- Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Espad Pharmed
Keratoconus
Evaluation of Safety and Efficacy of a Bioengineered Corneal Implant for Treatment of Keratoconus
This is a prospective, Phase I open-label safety study to evaluate the safety, feasibility and initial efficacy of a bioengineered corneal stromal substitute after implantation into the stroma of adults with advanced keratoconus.
- Trial name
- LinkCor (NCT04653922)
- Testing
- LinkCor Bioengineered Corneal Implant
- Where
- 2 sites in India, Iran
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- LinkoCare Life Sciences AB
Mid Face Volume Deficit
Evaluation of Efficacy and Safety of Alcarisa (Hyaluronic Acid Produced by Espad Pharmed Co.) for Restoration of Mid-face Volume
Mid-face volume loss is a factor affecting beauty that makes people feel uncomfortable about themselves. The purpose of this study is to evaluate the efficacy and safety of Hyaluronic Acid injection with the brand name Alcarisa®…
- Trial name
- NCT07126912
- Testing
- Alcarisa (hyaluronic acid filler)
- Where
- 2 sites in Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Alopecia Totalis/Universalis, Alopecia Areata(AA)
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia.
- Trial name
- NCT07101471
- Testing
- Tofacitinib
- Where
- Iran
- Volunteers
- 296 people
- Sponsor
- NanoAlvand
Nasolabial Fold Correction
Evaluation of Efficacy and Safety of Intella Dermal Filler in Moderate to Severe Nasolabial Folds
This single-arm, before-and-after clinical trial evaluated the safety and efficacy of Intella, a combined CaHA and HA dermal filler manufactured by Espad Pharmed Darou Co., for the correction of moderate to severe nasolabial…
- Trial name
- NCT07102537
- Testing
- Hyaluronic acid combined with calcium hydroxyapatite injection
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed
Migraine Disorders
Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks
Canvert-M (manufactured by Alasht Pharmed Co. Iran) is a topical roll-on formulation that contains cannabidiol, peppermint, lavender, rosemary, eucalyptus, wintergreen, basil oil, etc.
- Trial name
- NCT07093138
- Testing
- Canvert-M (Produced by Alasht Pharmed co. Iran)
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Alasht Pharmed
Lipoma
Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas
Lipoma is a relatively common, slow-growing mesenchymal neoplasm originating from adipose tissue. Patients seek treatment for lipomas for various reasons, such as concerns about their growth and spread, aesthetic issues, or…
- Trial name
- NCT07014163
- Testing
- Embella (Deoxycholic acid, produced by Espad Pharmed Co.)
- Where
- 2 sites in Iran
- Volunteers
- 10 people
- Sponsor
- Espad Pharmed
Glabellar Lines, Glabellar Frown Lines
A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
The aim of this study is to evaluate the efficacy and safety of AbobotulinumtoxinA (produced by Espad Pharmed Darou Co.) for correction of moderate to severe glabellar lines.
- Trial name
- NCT06946160
- Testing
- Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.)
- Where
- Iran
- Volunteers
- 146 people
- Sponsor
- Espad Pharmed
Glioma Glioblastoma Multiforme, High Grade Glioma (III or IV)
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults.
- Trial name
- NCT06687681
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Marzieh Ebrahimi
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Skin Aging
Evaluation of Effectiveness and Safety of Stabilized Injectable Hyaluronic Acid (Perleux Body, Produced by Espad Pharmed Company) in the Neck Area
This study aimed to evaluate the safety and effectiveness of stabilized Hyaluronic Acid Injection under the brand name Perleux body for neck skin rejuvenation, elasticity improvement, and hydration enhancement.
- Trial name
- NCT06844760
- Testing
- Hyaluronic Acid (HA)
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Espad Pharmed